Skip to main content
. 2014 Oct 7;125(2):284–295. doi: 10.1182/blood-2014-06-583518

Figure 5.

Figure 5

OSU-T315 inhibits BCR-, CD40L-, and CpG-induced survival signal. (A) CLL cells were treated with either plate-bounded α-IgM, 0.5 μg/ml CD40L, 3.2 μM CpG-ODN, or (C) plate-bound fibronectin or 1 μg/ml VCAM-1 combined with vehicle or 4 μM OSU-T315 for 15 minutes. The total lysate was subjected to immunoblotting. (B,D) Data from individual patients were quantified for p-AKT level and normalized to GAPDH. (E-G) Cell viability was examined after 24 hours in the treated conditions of plate-bounded α-IgM, 0.5 μg/ml CD40L, or 3.2 μM CpG-ODN combined with vehicle or different doses of OSU-T315.